Unknown

Dataset Information

0

Phenotypic Approaches to Identify Inhibitors of B Cell Activation.


ABSTRACT: An EPIC label-free phenotypic platform was developed to explore B cell receptor (BCR) and CD40R-mediated B cell activation. The phenotypic assay measured the association of RL non-Hodgkin's lymphoma B cells expressing lymphocyte function-associated antigen 1 (LFA-1) to intercellular adhesion molecule 1 (ICAM-1)-coated EPIC plates. Anti-IgM (immunoglobulin M) mediated BCR activation elicited a response that was blocked by LFA-1/ICAM-1 specific inhibitors and a panel of Bruton's tyrosine kinase (BTK) inhibitors. LFA-1/ICAM-1 association was further increased on coapplication of anti-IgM and mega CD40L when compared to individual application of either. Anti-IgM, mega CD40L, or the combination of both displayed distinct kinetic profiles that were inhibited by treatment with a BTK inhibitor. We also established a FLIPR-based assay to measure B cell activation in Ramos Burkitt's lymphoma B cells and an RL cell line. Anti-IgM-mediated BCR activation elicited a robust calcium response that was inhibited by a panel of BTK inhibitors. Conversely, CD40R activation did not elicit a calcium response in the FLIPR assay. Compared to the FLIPR, the EPIC assay has the propensity to identify inhibitors of both BCR and CD40R-mediated B cell activation and may provide more pharmacological depth or novel mechanisms of action for inhibition of B cell activation.

SUBMITTER: Rex EB 

PROVIDER: S-EPMC4512518 | BioStudies | 2015-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5093209 | BioStudies
2018-01-01 | S-EPMC6305442 | BioStudies
2020-01-01 | S-EPMC7266284 | BioStudies
2017-01-01 | S-EPMC5428509 | BioStudies
2015-01-01 | S-EPMC4369401 | BioStudies
2010-01-01 | S-EPMC2891581 | BioStudies
2005-01-01 | S-EPMC2213268 | BioStudies
1000-01-01 | S-EPMC3243613 | BioStudies
2009-11-25 | GSE15606 | GEO
2012-07-10 | E-GEOD-35748 | ArrayExpress